US Edition
Published • loading... • Updated
Larimar Reports Results, Advances Nomlabofusp Toward FDA Filing
Summary by MyChesCo
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Larimar Reports Results, Advances Nomlabofusp Toward FDA Filing
BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) reported fourth-quarter and full-year 2025 financial results while advancing its lead candidate nomlabofusp toward a planned FDA filing for the treatment of Friedreich’s ataxia, the company announced. The U.S. Food and Drug Administration granted Breakthrough Therapy Designation to nomlabofusp for adults and children with the condition, based on clinical data from an ongoing open-label …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
